Navigation Links
FDA's Hydroxycut Recall Highlights the Need for Stem Cell Innovations' ACTIVTox Human Liver Testing

HOUSTON, May 21 /PRNewswire-FirstCall/ -- Stem Cell Innovations' (Pink Sheets: SCLL) ACTIVTox(R) human liver toxicity tests are the only products on the market using a standardized human liver cell line to identify potential toxicities associated with nutraceuticals and dietary supplements. This system is available now and can be used to help prevent future liver-related damage and death.

"The use of our ACTIVTox testing system could help prevent recalls associated with liver toxicity," said James H. Kelly, PhD, CEO of Stem Cell Innovations, Inc. "ACTIVTox allows manufacturers to evaluate potential liver issues before release. This can be particularly important in the use of botanical extracts where both growing conditions and the extraction procedure can have dramatic effects on the composition of the final product."

ACTIVTox is designed to identify human liver toxicities associated with drugs, nutraceuticals and food supplements. "Consumers often have the impression that plant-based products are totally benign where, in fact, many of the most potent chemicals ever identified are plant products," said Kelly. "Particularly with the complex manufacturing challenges associated with the use of crude plant extracts, cell-based testing can give an extra measure of comfort to both the consumer and the producer. Considering the cost of developing, manufacturing and marketing new products, ACTIVTox testing protects your investment."

About Stem Cell Innovations, Inc.

SCLL is a cell biology company based in Houston, TX. The Company's ACTIVTox system is a human liver based model for high throughput toxicity testing. Stem Cell Innovations proprietary, human pluripotent stem cells, known as PluriCells, have the potential to aid in drug discovery, toxicology, and cell therapy.

Additional information is available at and at

ACTIVTox and PluriCells are Trademarks of Stem Cell Innovations, Inc.

Forward Looking Statement

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.

If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the difference could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.

SOURCE Stem Cell Innovations, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Max Muscle Sports Nutrition Offers Support for Hydroxycut Recall
2. Dieters Dealt a Body Blow From Recent Labeling of Hydroxycut as Unsafe for Human Consumption
3. Williams Kherkher Warns of Liver Damage, Failure from Hydroxycut
4. CRN Supports Recall of Hydroxycut Products
5. Biosite Incorporated Issues Voluntary, Nationwide Recall for Cardiac Marker Test
6. De Jong Bros. Recalls Spinach Because of Possible Health Risk
7. FDA Recalls Dietary Supplements Tied to 1 Death, Liver Damage
8. National Archives Recalls Flu Pandemic of 1918
9. Setton Pistachio of Terra Bella, Inc. Expands Voluntary Recall of Pistachios
10. Kroger Recalls Lite Mayo Due to Possible Health Risk
11. Caraco Pharmaceutical Laboratories, Ltd. Announces a Nationwide Voluntary Recall of All Lots of Digoxin Tablets Due to Size Variability
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... Califia Farms ... announced that its iconic bottle has won top honors in Beverage World Magazine’s Global ... Company also announced that it has been selected as a 2015 U.S.A. Taste Champion ...
(Date:12/1/2015)... MD (PRWEB) , ... December 01, 2015 , ... ... salmon identification tests to continue the expansion of the company’s growing product line ... – for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to ...
(Date:12/1/2015)... ... December 01, 2015 , ... The ... been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first portable ... Meeting from November 29 to December 4, 2015. , MED-TAB is expected ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... is everything. That is why Hollister Incorporated has launched the VaPro Plus Pocket™ ... next product in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... today announced it has been awarded a fixed price per sprint agile development ... contract, valued at $34 million over five years, provides software engineering, infrastructure, as ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 --> ... Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, ... and Pipeline Analysis - Global Forecast to 2020", published by ... USD 73,529.2 Million by 2020 from USD 40,281.6 Million in ... Browse 37 market data ...
(Date:12/1/2015)... BANGALORE, India and PITTSBURGH ... TASE: MYL) today announced that it expects to be ... developing country markets funded by international donors, TLE400 (Tenofovir ... Efavirenz 400 mg) for $99 per patient, per year. ... to develop TLE400. The significantly reduced price could generate ...
(Date:12/1/2015)... , Dec. 1, 2015  AccuTEC Blades, a ... new corporate logo and brand identity program. The ... and engineering of bladed products where "the edge ... --> Serving manufacturers and distributors ... auto glass equipment, AccuTEC,s product lines include those ...
Breaking Medicine Technology: